21:59 , Jul 11, 2019 |  BC Innovations  |  Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
21:40 , Jul 11, 2019 |  BC Innovations  |  Distillery Therapeutics

Treating asthma, allergic diseases with mAbs against crystallized proteins

DISEASE CATEGORY: Inflammation INDICATION: Asthma argenx and VIB have developed antibodies against LGALS10 that could help treat asthma and other allergic airway diseases. Patients with severe asthma had crystals comprising LGALS10 in airway tissue and...
22:01 , Jun 10, 2019 |  BC Extra  |  Company News

Tilos takeout sees Merck tapping TGFβ to solve checkpoint resistance

In its ongoing quest to find combinations for Keytruda pembrolizumab, Merck is acquiring two-year-old Tilos for its ability to modulate TGFβ, a target that’s been gaining interest on the back of clinical data in immuno-oncology,...
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
08:39 , Apr 3, 2019 |  BC Extra  |  Financial News

AgomAb emerges from stealth with €21M series A

Agonist antibody company AgomAb emerged from stealth with a €21 million ($24 million) series A round led by V-Bio Ventures and Advent France Biotechnology to develop antibodies mimicking growth factors for tissue regeneration. AgomAb Therapeutics...
17:27 , Mar 22, 2019 |  BC Week In Review  |  Company News

argenx gets first milestone payment from AbbVie for immuno-oncology therapy

AbbVie started a Phase I trial of ABBV-151 to treat solid tumors, triggering a $30 million milestone payment to argenx. AbbVie Inc. (NYSE:ABBV) exercised an option in 2018 to exclusively license the antibody targeting leucine-rich...
16:13 , Feb 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient samples and mouse studies suggest an antibiotic cocktail or inhibiting IL22RA1 or IL-17A could help treat lung cancer. In tissue samples from patients with lung adenocarcinoma, levels of IL22RA1 were higher...
01:47 , Feb 8, 2019 |  BC Week In Review  |  Company News

Halozyme grants argenx access to Enhanze subcutaneous delivery tech

Halozyme Therapeutics Inc. (NASDAQ:HALO) granted argenx S.E. (NASDAQ:ARGX) exclusive rights to use Halozyme's Enhanze subcutaneous drug delivery technology in combination with any product targeting the human neonatal Fc receptor FcRn, including argenx lead compound efgartigimod...
19:35 , Jan 24, 2019 |  BC Innovations  |  Emerging Company Profile

Cabaletta’s CAAR Ts for autoimmunity

Cabaletta Bio Inc.’s CAAR T therapy is geared to treat B cell-mediated autoimmunity without wiping out all B cells. The company is betting an antigen-specific approach will yield efficacy without CARs’ safety drawbacks. Cabaletta spun...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...